IRLAB Therapeutics AB Class A(DE:6IRA)
€0.07+0.02 (+37.04%)
DE:6IRA
IRLAB Therapeutics AB Class A financials statements
€0.07
At close:+0.02 (+37.04%)
IRLAB Therapeutics AB Class A (6IRA) Income Statement
1 Followers
IRLAB Therapeutics AB Class A Income Statement
Last quarter (Q3 2026), IRLAB Therapeutics AB Class A's total revenue was kr6.93M, a decrease of 63.22% from the same quarter last year. In Q3, IRLAB Therapeutics AB Class A's net income was kr-13.15M. See IRLAB Therapeutics AB Class A’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| kr 57.46M | kr 94.63M | kr 5.68M | kr 61.14M | kr 207.78M | |
| kr -92.35M | kr -92.42M | kr -122.73M | kr -111.23M | kr 168.69M | |
| kr 144.48M | kr 33.45M | kr 58.03M | kr 174.25M | kr 116.11M | |
| Depreciation and Amortization | kr 4.32M | kr 4.58M | kr 4.32M | kr 3.98M | kr 3.47M |
| kr -88.03M | kr -68.07M | kr -173.32M | kr -109.13M | kr 56.05M | |
| kr -92.35M | kr -75.11M | kr -180.76M | kr -113.11M | kr 52.58M | |
| kr -17.66M | kr -8.02M | kr 2.93M | kr -296.00K | kr -795.00K | |
| kr -110.01M | kr -83.13M | kr -177.84M | kr -113.41M | kr 51.78M | |
| kr -110.01M | kr -83.13M | kr -177.84M | kr -114.20M | kr 51.78M | |
| Per Share Metrics | |||||
| Basic EPS | kr -1.64 | kr -1.60 | kr -3.43 | kr -2.20 | kr 1.00 |
| Diluted EPS | kr -1.64 | kr -1.60 | kr -3.43 | kr -2.20 | kr 1.00 |
| Weighted Average Shares Outstanding | 67.00M | 51.87M | 51.87M | 51.83M | 51.75M |
| Weighted Average Shares Outstanding (Diluted) | 67.00M | 51.87M | 51.87M | 51.83M | 51.75M |
Currency in SEK

